OncoSil Medical (ASX:OSL) randomized the first patient at Royal Adelaide Hospital in South Australia for the TRIPP-FFX clinical trial for pancreatic cancer treatment, marking the start of patient recruitment at the hospital, according to a Tuesday filing with the Australian bourse.
The trial aims to evaluate the safety and effectiveness of the OncoSil device in conjunction with Folfirinox chemotherapy, the filing said.
Royal Adelaide Hospital's first randomized patient has increased the global TRIPP-FFX trial enrollment to 49, according to the filing.
Shares rose nearly 17% in morning trade Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.